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or opioid agonist. 
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Figure 4. 
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Figure 5 
(a) COC12, CHZCIZ, TEA, t I 0 oc, Argon. (b) NTX, CH2C12,TEA, t z 0 oc, Argon. (c) 
NTXOL, CHZCIZ, TEA, t = 0 cc, Argon. 
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3 A schematic diagram showing stepwise hydrolytic cleavage of the carbonate codrug 25, 
into NTX and BUOH in isotonic phosphate buffer, pH 7.4 at 32°C. 
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FIGURE 7 
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FIGURE 8 
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ENHANCING TRANSDERMAL DELIVERY 
OF OPIOID ANTAGONISTS AND AGONISTS 
USING CODRUGS LINKED TO BUPROPION 
OR HYDROXYBUPROPION 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority under 35 USC §119 to 
US. Provisional Application No. 60/853,761 ?led Oct. 24, 
2006 and US. Provisional Application No. 60/852,394 ?led 
Oct. 18, 2006, the disclosures of Which are incorporated 
herein by reference. 
GOVERNMENT INTERESTS 
A portion of this invention Was made With US. Govem 
ment support under a grant from the National Institutes of 
Health under NIH Grant R0lAA0l3853. The Government 
may have certain rights in this invention. 
FIELD OF THE INVENTION 
This invention relates to novel codrugs, and more particu 
larly to novel codrugs comprising bupropion or hydroxybu 
propion and an opioid antagonist or an opioid agonist joined 
together by chemical bonding. The codrugs possess increased 
bioavailability as compared to the parent drugs. 
BACKGROUND OF THE INVENTION 
Transdermal delivery is desirable to reduce the side effects 
associated With the oral administration of drugs. Such side 
effects can include abdominal pain, nausea and vomiting. 
Further, transdermal delivery offers a patient freedom from 
injections and surgical implantations. Transdermal delivery 
also bypasses the signi?cant metabolism associated With oral 
administration of drugs. Transdermal delivery is generally 
provided through a transdermal patch Which provides sus 
tained release of a drug. 
FolloWing its application to the skin, the therapeutic e?i 
cacy of a drug for transdermal delivery mainly depends on its 
ability to penetrate the skin fast enough to provide the plasma 
concentrations required to elicit the desired pharmacological 
activity. A large majority of drugs are unable to cross the skin 
at therapeutic rates due to the barrier imposed by the skin’s 
outer stratum corneum layer. Thus, the main challenge in 
transdermal drug delivery is providing su?icient drug pen 
etration across the skin. Skin permeability can be increased 
through the use of chemical enhancers, electrical enhancers 
via electroporation or iontophoresis, ultrasonic enhancers, 
and a variety of other approaches. Although these enhance 
ment technologies are still under active investigation, deliv 
er‘ing macromolecules into the skin remains a signi?cant 
challenge. See, e.g., Park et al., J. Control. Release 104 (2005) 
51-66 and Martanto et al., Pharrn. Res. 21 (2004). One ofthe 
strategies used to enhance skin permeation of poorly perme 
able drugs is the codrug approach. 
A codrug comprises tWo different drugs Within a single 
chemical entity. The tWo drugs may be connected either 
directly or by means of a cleavable, biolabile covalent linker. 
Many diseases are treated by a combination of therapeutic 
agents that are co-administered in separate dosage forms. 
HoWever; there are potential advantages in delivering the 
co-administered agents as a single chemical entity. One 
advantage is that often, When the tWo drugs are chemically 
linked together in the codrug structure, the resulting physico 
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chemical and pharmacokinetic properties of the codrug are 
superior to those of the individual parent drugs. Thus, careful 
design of the codrug entity can afford a unique product that 
may have superior physicochemical properties for drug deliv 
ery, compared to those of the individual drug entities them 
selves, leading to improved pharmaceutical properties. In 
addition, there are also other factors, such as the ability to 
control drug delivery by appropriate design of the biolabile 
linker(s) connecting the tWo drug entities, and the effect that 
simultaneous delivery of the tWo drugs, as one chemical 
entity, Will have on the pharrnacokinetics of each respective 
drug. Because the skin and plasma have an abundance of 
esterase enZymes, codrugs With esterase-susceptible linkages 
can be cleaved by these enZymes to release the active parent 
drugs in tissue and plasma. 
A codrug or a mutual prodrug consists of tWo drugs chemi 
cally linked together in order to improve the drug delivery 
properties of one or both drugs. This unique concept of a 
codrug has been utiliZed to improve ocular delivery of an 
antiglaucoma agent, ethacrynic acid (CynkoWska et al., 
Bioorganic & Medicinal Chemistry Letters 15 (2005) 3524 
3527). Other examples of codrugs include facilitated gas 
trointestinal absorption of loW molecular Weight heparin 
(LMWH) via conjugation to deoxycholic acid (DOCA) to 
form LMWH-DOCA (Lee et al., J. Control. Release 111 
(2006) 290-298) and dual-acting thromboxane antagonist 
synthase inhibitors (BroWn et al., Bioorganic & Medicinal 
Chemistry Letters 6 (1996) 273-278). 
Opioid agonists are useful for treatment of a number of 
conditions, including chronic pain, acute pain and depres 
sion. Opioid antagonists are useful for treatment of alcohol 
dependence, opioid addiction, and smoking. Naltrexone 
(N TX), for example, is an opioid antagonist used in the treat 
ment of opiate addiction and alcohol dependence (Volpicelli 
et al., Arch Gen Psychiatry 49 (1992) 876-80 and Wand et al., 
Alcohol Clin Exp Res 24 (2000) 1385-91). 6-[3-naltrexol 
(N TXOL) is the active metabolite of NIX (Volpicelli, Lancet 
346 (1995) 456 and Verebey et al., Clin Pharmacol Ther 20 
(1976) 315-28). Naltrexone is currently available as 
REVIA®, an FDA approved 50 mg tablet of Naltrexone 
Hydrochloride, and as VIVITROLTM, the recently FDA 
approved 28-day controlled release 380 mg depot form of 
Naltrexone. HoWever, REVIA® is poorly bioavailable, With 
documented side effects (PDR, Medical Economics, 1996, 
2229-2233, NeW Jersey). In addition, although long-lasting 
Naltrexone depot formulations have shoWn plasma levels for 
up to 30 days (GalloWay et al., BMC Psychiatry 5 (2005) 18), 
once VIVITROLTM is injected, it cannot be easily discontin 
ued Without painful surgical removal. There is a need for 
methods for transdermally transporting a therapeutically 
effective amount of opioid antagonists and agonists, such as 
Naltrexone, in order to provide bene?ts such as controlled 
release, reduced side effects, and the ability to readily discon 
tinue therapy. 
Bupropion (BUP) is an aminoketone used as an antidepres 
sant and non-nicotine aid to smoking cessation (Johnston et 
al., Nicotine Tob Res 3 (2001) 131-40). The pharmacological 
activity of BUP might be due to, or receive substantial con 
tributions from its major active human metabolite, hydroxy 
bupropion (BUPOH) (Schroeder, J Clin Psychiatry 44 (1983) 
79-81 and Belson and Kelley, J Emerg Med 23 (2002) 223 
30). Both BUP and BUPOH have excellent physicochemical 
properties that alloW for transdermal delivery, and chemical 
linkage to BUP or BUPOH should improve the skin perme 
ability characteristics of opioid antagonists and agonists. 
The present invention is directed to novel codrugs com 
prising bupropion or hydroxybupropion and an opioid 
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antagonist or an opioid agonist joined together by chemical 
bonding. The codrugs provide a signi?cant increase in the 
transdermal ?ux across human skin, as compared to the basic 
opioid antagonist or opioid agonist. Preferably, the opioid 
antagonist is NTX or NTXOL. The codrug of the present 
invention may increase the transdermal drug delivery rate 
either by a solubility improvement or by a permeability 
improvement, or a combination of both. 
SUMMARY OF THE INVENTION 
In one aspect, the present invention provides a novel 
codrug, Which improves the oral bioavailability of the com 
ponent drugs. The term “codrug” as used in the speci?cation 
and claims means tWo different drugs joined together by 
chemical bonding. In the codrug of the present invention, one 
of the drugs is BUP or BUPOH. The other drug is an opioid 
antagonist or an opioid agonist. The drugs must have one or 
more connecting bonds or groups. On introduction of the 
codrug into the body, the chemical bond is disrupted and the 
drugs become available for their intended purposes. 
The present invention further provides for a method for 
delivery of the codrug components by biotransforming the 
codrug into tWo active drug molecules by hydrolysis or enZy 
matic digestion. The term “biotransforming” as used herein 
means using Water or enZymes to cleave the connecting bond 
or group, thereby causing the codrug to be transformed into 
the active parent drug molecules. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs chemical structures of naltrexone (NTX, 1), 
6-[3-naltrexol (NTXOL, 2), bupropion (BUP, 3), and 
hydroxybupropion (BUPOH, 4). 
FIG. 2 shoWs codrugs of hydroxybupropion With naltrex 
one and naltrexol. 
FIGS. 3-6 shoW codrug synthesis steps. 
FIG. 7 shoWs a hydrolytic pro?le of the carbonate codrug 
(25) shoWing the hydrolysis into NTX and BUPOH in iso 
tonic phosphate buffer pH 7.4 at 32° C. 
FIG. 8. shoWs a chemical structure of the carbonate codrug, 
CB-NTXOL-BUPOH, consisting of 6-[3-naltrexol covalently 
linked to a form of hydroxybupropion. 
FIG. 9. is a schematic diagram illustrating the hydrolytic 
pathWay of CB-NTXOL-BUPOH to give 6-[3-naltrexol and 
hydroxybupropion. 
FIG. 10. shoWs a hydrolysis pro?le of the carbonate 
codrug, CB-NTXOL-BUPOH, regenerating into 6-[3-naltr 
exol and hydroxybupropion in isotonic phosphate buffer pH 
7.4 at 32° C. Solid lines represent predicted pro?les of the 
drugs With time and data is represented as mean:s.d. 
FIG. 11. is a representative permeation pro?le from satu 
rated solutions of the carbonate codrug and 6-[3-naltrexol 
(control) through human skin in vitro at 32° C. Data is rep 
resented as meaniSD (n:4 for CB-NTXOL-BUPOH treat 
ment and n:3 for 6-[3-naltrexol treatment). 
FIG. 12. shoWs the drug concentration of the carbonate 
codrug and parent drugs in the skin after a 48 h diffusion study 
folloWing application of drugs as saturated solutions in light 
mineral oil. Data is represented as meaniSD. 
FIG. 13. is a hydrolysis pro?le of the carbonate codrug, 
CB-NTXOL-BUPOH, in guinea pig plasma at 37° C. 
FIG. 14. shoWs mean (:S.D.) plasma concentration pro 
?les in guinea pigs after topical application of a gel formula 
tion containing either CB-NTXOL-BUPOH (n:6) or 6-6 
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naltrexol (control, n:5). The dotted line (----) indicates the 
plasma concentration after the removal of the formulation. 
DESCRIPTION OF THE INVENTION 
The present invention relates to codrugs comprising BUP 
or BUPOH and an opioid antagonist or an opioid agonist 
joined together by chemical bonding. According to the 
present invention, it has been discovered that the novel 
codrugs of the invention provide a signi?cant increase in the 
transdermal ?ux of the codrugs across human skin, as com 
pared to the basic opioid antagonists and agonists. 
Preferably, the codrug comprises one molecule of BUP or 
BUPOH and one molecule of an opioid antagonist or an 
opioid agonist j oined together by chemical bonding. BUPOH 
is preferred. 
Suitable opioid agonists and antagonists include Naltrex 
one, Buprenorphine, Butorphanol, Codeine, Dihydroco 
deine, Dihydromorphine, Ethymorphine, Hydromorphone, 
Levallorphan, Levorphanol, Nalbuphine, Nalmefene, Nalor 
phine, Naloxone, 6-[3-Naltrexol, PhenaZocine, Pholcodine, or 
6-0t-Naltrexol. Preferred opioid antagonists are Naltrexone 
and 6-[3-Naltrexol. 6-[3-Naltrexol is particularly preferred. 
The codrug comprises one or more connecting bonds or 
groups. The BUP or BUPOH and opioid antagonist or opioid 
agonist can be linked together via one or more cleavable 
linker moieties such as ester, thioester, carbonate, carbamate, 
thiocarbamate, amide, thioamide, ureide, or any other suit 
able chemical moieties providing that the chemistry is fea 
sible. Preferably, the codrug comprises a carbonate ester link 
age. 
The linker moiety is preferably bioconvertible or biolabile. 
More preferably, the linker moiety is cleavable via hydrolysis 
or enzymatic digestion. 
As shoWn in the present examples, a codrug comprising 
one molecule of 6-[3-naltrexol and one molecule of BUPOH 
provides an unexpected increase of 6-[3-naltrexol maximum 
?ux rate across the skin. Similar results Would be expected for 
other codrugs set forth above. 
The present invention also relates to methods for treating 
conditions including pain, depression, narcotic dependence 
and drug addiction. Subjects Who can bene?t from the meth 
ods of the present invention include, for example, mammals, 
such as humans, particularly humans Who are suffering from 
pain, depression, narcotic dependence, alcohol abuse, and/or 
alcoholism. 
“Treatment” or “treating,” as used herein, refers to com 
plete elimination as Well as to any clinically or quantitatively 
measurable reduction in condition for Which the subject is 
being treated. The methods of the present invention involve 
delivering a therapeutically effective amount of the codrug. A 
“therapeutically effective amount,” as used herein, refers to 
an amount, determined by one skilled in the art, su?icient for 
treating the condition for Which the subject is being treated. 
The codrug can be delivered to a subject transdermally, 
intravenously, orally, buccally, sublingually, by topical 
creams, subderrnally, as a sustained release depot, ophthalmi 
cally, intranasally, aurally, by inhalation, rectally or vaginally. 
After delivery, the codrug is preferably biotransformed by 
hydrolysis or enZymatic activity into at least tWo active drug 
molecules. 
Transderrnal delivery is preferred. In a method for trans 
dermal delivery of the codrug, the steps comprise contacting 
a section of human skin With the codrug and biotransforming 
the codrug into tWo drugs by skin enZymes or by hydrolysis of 
the codrug in the skin. A transdermal patch comprising a 
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suitable substrate and a layer of the codrug can be employed 
to deliver the codrug to the skin. 
The codrug is preferably administered as a pharmaceutical 
composition comprising pharmaceutically acceptable carri 
ers, diluents, and/or excipients, Which are vehicles commonly 
used to formulate pharmaceutical compositions for animal or 
human administration. The carriers, diluents and/or excipi 
ents are not intended to have biological activity themselves, 
and are selected so as not to affect the biological activity of the 
codrug and any other active agent(s). A pharmaceutically 
acceptable carrier, diluent, and/or excipient as used herein 
includes both one and more than one such carrier, diluent, 
and/or excipient. Examples include but are not limited to 
distilled Water, saline, physiological phosphate-buffered 
saline, Ringer’s solutions, dextrose solution, and Hank’s 
solution. Depending upon the manner of introduction, the 
codrug may be formulated as, for example, a sterile injectable 
formulation comprising aqueous solutions and/or suspen 
sions containing the active materials in admixture With suit 
able carriers, diluents, and/or excipients. 
The concentration of codrug, the formulation (i.e., a for 
mulation that is therapeutically effective to the subject to 
Which it is administered) and the dose administered can be 
readily determined by a person of ordinary skill in the art. 
Typically, dosages used in vitro and in animal models, such as 
in the experiments provided in the present application, may 
provide useful guidance in the amounts useful for in vivo 
administration. 
The codrug can be applied to the skin as a topical cream, 
salve, ointment, gel, or other topical formulation; and/or by 
using delivery devices such as bandages, occlusive bodies, 
patches, and/or the like. The area of skin to Which the codrug 
is applied can optional be pre-treated With microneedles or 
other permeability enhancers (see, e. g., Park et al., J. Control. 
Release 104 (2005) 51-66 and PrausnitZ, Adv. Drug Deliv. 
Rev. 56 (2004) 581-587). 
Illustratively, a codrug composition that is applied to the 
skin can be formulated as a topical cream, salve, gel, or 
ointment. The topical formulations can include inert diluents 
and carriers as Well as other conventional excipients, such as 
Wetting agents, preservatives, and suspending and dispersing 
agents. In addition to the above, generally non-active compo 
nents, topical formulations containing codrug can further 
include other active materials, particularly, active materials 
Which have been identi?ed as useful in the treatment of the 
condition for Which the subject is being treated, for example 
drug and/or alcohol addiction, and Which can usefully be 
delivered transdermally to the subject. For instance, such 
other active materials can include acamprosate, disul?ram, 
topiramate, sertraline, rivastigmine, citalopram, and doxepin. 
The topical formulation canbe applied directly to the skin and 
then optionally covered (e.g., With a bandage of gauZe) to 
minimize the likelihood of its being disturbed. Alternatively, 
the topical formulation can be coated on the surface of a 
bandage, gauZe, etc., and the bandage, gauZe, etc. can then be 
applied to the skin of the subject such that the topical forrnu 
lation is in direct contact With the subj ect’s skin. 
Alternatively, the codrug can be delivered transdermally to 
the subject by formulating codrug into a bandage, pad, or 
other type of patch Which can be applied to the subject’s skin. 
Illustratively, matrix-type transdermal patches, in Which 
the codrug is disposed in an adhesive matrix, can be 
employed. The matrix-type transdermal patch can further 
include other active materials for transdermal delivery to the 
subject With the codrug. Suitable adhesives for use in such 
matrix-type transdermal patches include polyisobutylenes, 
acrylates, silicone, and combinations thereof. Still other 
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patches suitable for use in the practice of the present invention 
include those described in US. Pat. No. 5,223,262. 
In another illustrative embodiment, the bandage, pad, or 
other type of patch can be one Which is capable of controlling 
the release of the codrug such that transdermal delivery of the 
Codrug to the subject is substantially uniform and sustained 
over a period of at least 12 hours, such as at least 24 hours, at 
least 48 hours, and/or at least 7 days. Such a bandage, pad, or 
other type of patch Which can be used in the practice of the 
method of the present invention can take the form of an 
occlusive body. In practice, the occlusive body Which 
includes the codrug is positioned on the subject’s skin under 
conditions effective to transdermally deliver the codrug to the 
subject’s skin. 
Other aspects and advantages of the present invention Will 
be understood upon consideration of the folloWing illustrative 
examples. The examples are not to be construed in any Way as 
limiting the scope of this invention. 
EXAMPLES 
Example 1 
Synthesis and Hydrolytic Pro?le of Codrugs of 
Naltrexone and 6-[3-naltrexol With 
Hydroxybupropion 
1.1 Introduction 
Simultaneous treatment of alcohol abuse and tobacco 
dependence is considered very desirable because of substan 
tial evidence that smoking is increased signi?cantly during 
drinking (Mello, et al., Psychopharmacology 1987, 93 (1), 
8-15). It also appears that alcohol drinking is increased in the 
presence of nicotine; thus each addiction exacerbates the 
other (KoZloWski, et al., J. Subst. Abuse Treat. 1993, 10 (2), 
171-179; Mitchell, et al., Behav. Pharmacol. 1995, 6, 359 
365; Glautier, et al., Behav. Pharmacol. 1996, 7, 144-154; 
Smith, et al., Psychopharmacalogy 1999, 142, 408-412; and 
Watson, et al., Neuropharmacology 1999, 38, 587-595). 
Opioid addicts also have a high prevalence of tobacco depen 
dency and associated co-abuse problems, and Would bene?t 
from a co-therapy approach. (Frosch, et al., Clin. Psychop 
harmacology. 2000, 8 (1), 97-103). 
Naltrexone (NTX, 1) (FIG. 1) is an opioid antagonist used 
in the treatment of opioid addiction and alcohol dependence 
(Volpicelli, et al., Arch Gen Psychiatry 1992, 49, 876-880). 
HoWever, NTX is a hepatotoxin that has been demonstrated to 
have loW oral bioavailability, and adverse side effects, such as 
abdominal pain, constipation, nausea, and vomiting. Trans 
dermal delivery is a desirable alternative route of admini stra 
tion for NTX, since it helps reduce side effects associated 
With oral therapy, and improves compliance (RohsenoW, et 
al., Alcoholism: Clinical and Experimental Research. 2000, 
24(10), 1542-1549). Unfortunately, NTX itself does not have 
the necessary physicochemical properties that Would alloW a 
therapeutic dose of the drug to cross the human skin barrier. In 
recent years, improved transdermal drug delivery has been 
achieved utiliZing more lipophilic prodrugs of NTX, Which 
are more skin permeable than NTX (Stinchcomb, et al., J. 
Pharm. Sci. 2002, 91, 2571-2578; Pillai, et al., Pharm. Res. 
2004, 21, 1146-1152;Vaddi, etal.,Pharm. Res. 2005, 22 (5), 
758-765; and Valiveti, et al., J. Contr Rel. 2005, 102(2), 
509-520). This same approach can be utiliZed in the design of 
synergistic codrugs of either NTX or [3-naltrexol (NTXOL, 2) 
(FIG. 1), the active metabolite of NTX (McCaul, et al., Alca 
hol: Clin. Exp. Res. 2000, 24(9), 1385-1391; Rukstalis, et al., 
Clin. Exp. Res. 2000, 24(10), 1593-1596; Porter, et al., British 
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Journal ofClinicalPharmacology 2000, 50(5), 465-471; and 
Wang, et al., Journal ofNeurochemisZry 2001, 77(6), 1590 
1 600). 
Bupropion (BUP, 3) (FIG. 1) is an antidepressant medica 
tion and a therapeutic agent currently used in the treatment of 
nicotine dependence as a smoking cessation agent. Hydroxy 
bupropion (BUPOH, 4) (FIG. 1), is the major metabolite of 
BUP, and is believed to contribute to its antidepressant activ 
ity, as Well as the smoking-cessation properties of BUP (Coo 
per, et al., Neuropsychopharmacology 1994 (1994), 11 (2), 
133-141; Ascher, et al., Journal of Clinical Psychiatry 1995, 
56 (9), 395-401; Sanchez and Hyttel, J. Cell. Mol. Neurobiol. 
1999, 19 (4), 467-489; Slemmer, et al., JPET 2000, 295(1), 
321-327). It is likely that BUP may be acting as a nicotinic 
receptor antagonist, and that this property is responsible for 
the smoking cessation properties of the drug (Slemmer, et al., 
2000). BUP and BUPOH are drug molecules that are consid 
ered ideally suitable, from both a chemical and pharmaco 
logical perspective, for covalent linkage to NTX and NT'XOL 
to afford clinically useful codrug entities for the treatment of 
both alcohol abuse and tobacco dependence. Both NTX and 
BUP are administered in therapeutic doses that are similar, on 
a molar ratio basis, indicating that a 1:1 ratio of these tWo 
drugs in a codrug entity Would have therapeutic potential. 
The present invention includes a series of novel NTX and 
NTXOL codrugs covalently linked to either BUP or BUPOH 
via an enZymatically cleavable linker moiety. These mol 
ecules Were designed to determine if such codrugs could 
increase the delivery rate of NTX and NTXOL across human 
skin When covalently linked to either BUP or BUPOH. If 
successful, this approach could improve pharmacotherapy for 
both alcohol abuse and tobacco dependency by providing a 
single, clinically effective, transdermal codrug dosage form 
to treat both co-dependent conditions. 
Thus, the main therapeutic goal of this approach Was to 
design a codrug that could afford a transdermal ?ux from 2.8 
toz12-90 nmol/cm2/hr across the skin, folloWed by rapid 
metabolism of the codrug to achieve therapeutically effective 
levels of the tWo parent drugs in the body. The conversion of 
the highly crystalline and high melting NTX to a covalently 
linked codrug With BUP or BUPOH should afford a loWer 
melting and more lipid soluble molecule. Drugs With high 
melting points often have corresponding loW oil solubilities 
(Stinchcomb, et al., Pharm. Res. 1995, 2, 1526-1529). Trans 
dermal delivery of a drug is in part related to it’s lipid solu 
bility, as this establishes the limit of attainable driving force 
across the skin (Flynn, In Principles of Roule-lo-Roule 
Exlrapolalionfor RiskAssessmenZ. 1990, Gerrity, T. R.; and 
Henry, C, J. (eds.), Elsevier, N.Y., 93-127). Increased lipo 
philicity of a drug causes an increase in its skin permeability 
up to a maximum. Thus, the codrug design Was utiliZed to 
push the lipophilicity envelope to its optimal value, in order to 
take advantage of maximal transdermal ?ux, but also to avoid 
problems of viable tissue controlled diffusion. (Stinchcomb, 
et al., Pharm. Res. 1995, 2, 1526-1529). 
1.2 Results and Discussion 
Chemistry 
A codrug is formed by chemical conjugation of tWo or 
more drugs via a suitably designed labile linker unit. The 
drugs are usually linked via linker moieties, such as ester, 
carbonate, amide, carbamate, etc., Which are then cleaved 
enZymatically to regenerate the active drug molecules at a 
required site in the body. 
In efforts to synthesiZe the carbonate codrugs 7 & 8 (FIG. 
3), Which are codrugs of BUP covalently linked to either NTX 
or NTXOL, initial coupling of the tWo molecules utiliZing 
phosgene as the linker precursor Was attempted. Firstly, 
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N-acylation reaction conditions (FIG. 3) utiliZing bupropion 
and phos gene under a variety of conditions and solvents in the 
presence of triethylamine, folloWed by addition of NTX, 
afforded the stable cyclic product 9 and unreacted NTX. 
When BUP Was reacted With phosgene in the absence of 
NTX, 9 Was formed in good yield, rather than the expected 
chlorocarbonyl intermediate 5 (FIG. 3). This result indicates 
that the chlorocarbonyl intermediate 7 is not stable enough to 
be isolated, and its half-life appears to be too short for the 
reaction With NTX to occur. The formation of 9 can be 
explained by 5 existing in an equilibrium mixture With its enol 
tautomer 6, Which then undergoes rapid intramolecular 
O-acylation to form 9. 
Hussain (Hussain, et al., J. Pharm. Sci. 1987, 76, 356-358) 
and Nelson (Olsen, et al., J. Med. Chem. 1990, 33, 737-741) 
have reported the synthesis of a number of 3-O- and 6-O-ester 
analogs of NTX and NTXOL. These methodologies do not 
require protection of the C-14 hydroxyl group, due to its 
unreactivity, Which results from the signi?cant steric hin 
drance around this functional group. Under the reaction con 
ditions described by Hussain, O-acylation of NTX in the 
presence of base is regiospeci?c for the more reactive C-3 
phenolic group (as the phenolate anion). Similarly, O-acyla 
tion of NTXOL in the presence of base is regiospeci?c for the 
3-OH group (De Costa, et al., J. Med. Chem. 1992, 35, 2826 
2535). Thus, no prior protection of either the 14- or 6-[3OH 
group in either NTX or NTXOL is required for regiospeci?c 
3-O-acetylation of these molecules. With this in mind, in an 
alternative strategy, the synthesis of codrugs 7 and 8 via 
intermediate 10 (FIG. 4), Which Was formed from the reaction 
of NTX and phosgene in the presence of triethylamine, Was 
attempted. Under these conditions, the reaction of NTX With 
phosgene afforded exclusively the dimeric 3-O, 3'-O carbon 
ate ester of NTX (1 1, FIG. 4) rather than the expected NTX 
3-O-chlorocarbonyl intermediate 10. (Hammell, et al., Jour 
nal of Controlled Release 2004, 97(2), 283-290). Also, When 
this reaction Was carried out in the presence of BUP, both 11 
and 9 Were formed, and no codrug could be detected in the 
reaction mixture. The use of a variety of different reactions 
conditions in these reactions failed to yield the desired inter 
mediate 10, affording only 11 in good yield. Similarly, When 
NTXOL Was utiliZed in place of NTX, reaction With phos 
gene resulted in the formation of the corresponding dimeric 
3-O, 3'-O carbonate ester ofNTXOL, 13 (FIG. 4). 
Efforts to synthesiZe codrugs 14-17 (FIG. 2) of BUPOH 
With NTX or NTXOL Were also explored. The hemiketal 
form of BUPOH, 4, exists in equilibrium With its uncycliZed 
form, 18 (FIG. 5). Thus, if the hemiketal form of BUPOH, 4, 
is reacted With phosgene, then either the chlorocarbamate 
intermediate 19 (FIG. 5), the chlorocarbonate intermediate 20 
(FIG. 5), or both, could be formed, either of Which if coupled 
With NTX or NTXOL Would afford codrugs 14-17 (FIG. 2). 
Also, there is a possibility that the formation of 19 might be 
folloWed by ring opening, leading to the formation of 21 
(FIG. 5). On the other hand, if the ring-open form of BUPOH, 
18, reacts With phosgene, the chlorocarbamate intermediate, 
21, Would be expected to be formed. If 21 is stable enough to 
couple to NTX or NTXOL, it may undergo subsequent 
cycliZation to the hemiketal form, resulting in the formation 
of codrugs 14-17. Also, BUPOH may be initially N-chloro 
carbonylated to afford 21 , Which, like the corresponding BUP 
analog, 6, can exist in equilibrium With its enol tautomer, 22 
(FIG. 5), folloWed by rapid intramolecular O-acylation to 23 
(FIG. 5). When equimolar amounts of BUPOH and phosgene 
Were reacted under basic conditions, the phosgene-BUPOH 
US 8,653,271 B2 
intermediate 23 (FIG. 5) Was formed as the major product in 
the reaction. Compound 23 could be isolated, puri?ed and 
fully characterized. 
These results clearly indicate that the ring opened and 
cycliZed (hemiketal) forms of BUPOH are in dynamic equi 
librium under the conditions of the initial acylation reaction 
With phosgene (FIG. 5), although the possibility that 22 might 
be formed by ring opening of 19, if it is formed, cannot be 
excluded. Unlike the corresponding BUP analog, 9, interrne 
diate 23 has a terminal hydroxyl group that can be utiliZed for 
linking With NTX or NTXOL via a carbonate moiety. Fur 
thermore, the cyclic carbonate analog of BUPOH, 23, is 
expected to be enZymatically cleaved to BUPOH in vivo. 
Thus, this modi?ed BUPOH entity Was considered to be a 
valid substitute for BUPOH in BUPOH-NTX or BUPOH 
NTXOL codrug molecules. Also, When BUPOH Was reacted 
With excess phosgene under basic conditions, the intermedi 
ate 24 (FIG. 5) Was the major product in the reaction. Inter 
mediate 24 could be isolated and fully characteriZed, and 
afforded the modi?ed codrug 25 (FIG. 5) on treatment With 
NTX in dichloromethane. 
In a similar manner, the desired NTXOL-BUPOH codrug 
26 (FIG. 5) Was obtained When compound 24 Was reacted 
With NTXOL in dichloromethane in the presence of triethy 
lamine. These results again indicate that the ring opened and 
cycliZed (hemiketal) forms of BUPOH are in dynamic equi 
librium under the conditions of the initial N-chlorocarbony 
lation reaction With phosgene (FIG. 5). 
Hydrolysis Studies on Codrugs 25 and 26. 
Any drug that is to be formulated into a dosage form must 
exhibit stability in the medium that it is formulated in. On the 
other hand, the BUPOH-NTX/NTXOL codrugs must be 
capable of reverting back to the parent drugs in the body by 
enZymatic or chemical action. The reconversion rate must be 
adequate in order to deliver the active drugs effectively. In this 
respect, neither a codrug that degrades in its vehicle nor one 
that never reverts to the parent drugs has any therapeutic 
value. A codrug that does not have enough chemical stability 
to Withstand the rigors of transport across the stratum cor 
neum is equally Worthless. 
Although it is considered that codrugs 25 and 26 are likely 
to be cleaved enZymatically in vivo to generate BUPOH and 
NTX and BUPOH and NTXOL, respectively, initial studies 
on the hydrolysis of these codrugs in buffer at physiological 
pH should provide good evidence that the parent drugs Will be 
e?iciently formed. To determine Whether codrugs 25 and 26 
could be hydrolyZed to the parent drugs, hydrolysis studies 
Were carried out at physiological (pH 7.4) using isotonic 
phosphate buffer. Skin has been shoWn to be a metabolically 
active organ for NTX carbonate prodrugs. (Pillai, et al., 
Pharm. Res. 2004, 21, 1146-1152). Thus, these carbonate 
codrug molecules should also be susceptible to hydrolytic 
cleavage, and We anticipated the hydrolytic conversion to 
proceed as illustrated in FIG. 6. 
The chemical stability of the codrug 25 in isotonic phos 
phate buffer at pH 7.4 Was studied over 4 days. Concentration 
versus time curves for the appearance of the parent drugs 
NTX and BUPOH, and the disappearance of the carbonate 
codrug 25 are shoWn in FIG. 7. The ?rst-order rate constants 
kl and k3 Were calculated to be 0.0179 hr-1 and 0.0483 M“, 
respectively, for generation of NTX and BUPOH. 
Similarly, hydrolytic studies With codrug 26 Were also 
carried out, and the corresponding rate constants k1, and k2 
Were calculated to be 0.0240:0.0007 hr“1 and 00139100006 
M“, respectively. Thus, both codrugs 25 and 26 appear to 
hydrolyZe rapidly at the carbonate linker moiety to afford 
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NTX or NT'XOL folloWed by hydrolytic cleavage of the 
resulting cyclic BUPOH intermediate 23, to generate 
BUPOH. 
The Physicochemical Properties of the Codrugs. 
A more qualitative basis for the design of codrugs to 
enhance transdermal delivery of NTX or NTXOL is to 
improve the physicochemical properties essential for 
increased permeation through skin. Some of the physico 
chemical properties of codrugs 25 and 26 Were measured and 
compared to those for NTX or NTXOL, and these are shoWn 
in Table 1. 
TABLE 1 
Physicochernical properties of NTX, NTXOL, 
and the carbonate codrugs 25 and 26. 
Compound MW MP (0 C.) clog PI Half-life, tl/2 (hrs)* 
1 341.40 175.7 1 1.20 0.36 stable 
2 343.42 187.76 1 2.62 0.83 stable 
4 255.74 124.40 1 1.60 2.87 stable 
25 649.13 137.00 1 1.41 3.23 36.68 1 2.88 
26 651.15 159.501212 3.71 28.881282 
IDerived from Daylight ® Software 
*St'udied in isotonic phosphate buffer, pH 7.4 at 32° C. 
The melting points of the codrugs Were measured because. 
This physical property can be easily related to the drug solu 
bility properties. (Stinchcomb, et al., Pharm. Res. 1995, 2, 
1526-1529; Jain, et al., J. Pharrn. Sci. 2001, 90, 234-252). As 
shoWn in Table 1, the calculated clog P values Were found to 
be higher for the codrugs compared to those for the corre 
sponding parent drugs. The clog P value provides a Way of 
estimating the lipophilicity of a drug, and the higher the clog 
P value the more lipophilic the drug. Increased lipophilicity 
of a transdermal drug causes an increase in skin permeability 
and is primarily attributed to an increase in the partitioning of 
the drug into the skin. Another important physicochemical 
property necessary for enhancement of transdermal delivery 
is rapid bioconversion of the codrug to the corresponding 
parent drugs. Rapid bioconversion rates of codrugs are rep 
resented by short half-lives in isotonic phosphate buffer (pH 
7.4/32o C.), and these values can be signi?cantly increased in 
vivo, because in addition to hydrolysis, the codrugs are also 
susceptible to enZymatic action by esterases. In addition to 
regeneration of the active parent drugs, rapid bioconversion 
of the codrugs in the skin causes an enhancement of the 
concentration gradient across skin, and consequently leads to 
an increased potential of the drug to cross the skin barrier. 
1.3 Conclusions 
TWo novel codrugs of NTX and NTXOL With BUPOH 
have been synthesiZed, and the kinetics of their hydrolysis 
also studied. The physicochemical properties of these 25 and 
26 codrugs indicate that both codrugs have the capability to 
permeate the skin at a higher rate When compared to either 
NTX or NTXOL. Both codrugs Were hydrolyZed in isotonic 
phosphate buffer (pH 74/ 32° C.) and e?iciently released the 
parent drugs. Thus, the tWo codrugs 25 and 26 are predicted to 
be cleaved enZymatically in vivo to generate BUPOH and 
NTX, and BUPOH and NTXOL, respectively, representing 
potential candidates for transdermal delivery of these drug 
entities for the treatment of both alcohol abuse and tobacco 
dependency. 
1.4 Experimental Section 
Chemistry 
All purchased solvents and reagents Were used Without 
further puri?cation. Phosgene Was purchased from Fluka 
Chemie AS. (Note!!! Care must be exercised in the handling 












